#1 Clinical Trials Search in Europe

Giredestrant

Giredestrant is an innovative drug being studied in clinical trials for the treatment of breast cancer. This article explores the use of giredestrant in various clinical trials, focusing on its potential efficacy, safety, and applications for different types and stages of breast cancer. The trials investigate giredestrant alone and in combination with other therapies, providing valuable insights into its potential as a new treatment option for breast cancer patients.

Table of Contents

What is Giredestrant?

Giredestrant is a new medication being developed for the treatment of certain types of breast cancer. It is known by several names, including GDC-9545, RO7197597, and RG6171[1][2]. This drug is part of a class of medications called selective estrogen receptor degraders (SERDs), which are designed to target and break down estrogen receptors in cancer cells[2].

How Does Giredestrant Work?

Giredestrant works by targeting estrogen receptors in breast cancer cells. Estrogen receptors are proteins that, when activated by estrogen, can promote the growth of certain types of breast cancer. Giredestrant is a highly potent, non-steroidal, oral selective estrogen receptor antagonist and degrader (SERD)[3]. This means it not only blocks estrogen from binding to these receptors but also helps to break down the receptors themselves, potentially slowing or stopping the growth of cancer cells.

What Conditions Does Giredestrant Treat?

Giredestrant is primarily being studied for the treatment of estrogen receptor-positive (ER+), HER2-negative breast cancer. This type of breast cancer is driven by estrogen and does not have high levels of a protein called HER2. Giredestrant is being investigated for use in various stages of this type of breast cancer, including:

  • Early-stage breast cancer[4]
  • Locally advanced breast cancer (cancer that has spread to nearby tissues or lymph nodes)[5]
  • Metastatic breast cancer (cancer that has spread to other parts of the body)[5]

Clinical Trials and Research

Giredestrant is currently being studied in several clinical trials to evaluate its effectiveness and safety. These trials are comparing giredestrant to existing treatments and exploring its use in different combinations and stages of breast cancer. Some key studies include:

  • The persevERA Breast Cancer trial, which is comparing giredestrant combined with palbociclib (another cancer drug) to letrozole (a standard hormone therapy) combined with palbociclib in patients with advanced or metastatic breast cancer[5].
  • The coopERA Breast Cancer trial, which is evaluating giredestrant plus palbociclib compared to anastrozole (another hormone therapy) plus palbociclib in early-stage breast cancer[4].
  • The lidERA Breast Cancer trial, which is studying giredestrant as an adjuvant therapy (treatment given after primary treatment) compared to standard endocrine therapy in early breast cancer[6].

Administration and Dosage

Giredestrant is taken orally (by mouth) once daily. In most clinical trials, the dosage being studied is 30 milligrams (mg) per day[4][5]. It is typically taken on a continuous schedule, meaning every day of each 28-day treatment cycle. The exact dosage and schedule may vary depending on the specific trial or treatment plan.

Potential Side Effects

As with all medications, giredestrant may cause side effects. The full range of potential side effects is still being studied in clinical trials. Common side effects observed in cancer treatments may include fatigue, nausea, and changes in blood cell counts. Specific side effects related to giredestrant will be better understood as more data from clinical trials becomes available[4][5].

Future Prospects

Giredestrant shows promise as a potential new treatment option for patients with ER-positive, HER2-negative breast cancer. Ongoing research is exploring its effectiveness in various stages of breast cancer and in combination with other treatments. If successful in clinical trials, giredestrant could provide an additional option for patients, particularly those who may have developed resistance to current hormone therapies[7].

It’s important to note that giredestrant is still an investigational drug and is not yet approved for general use. Patients interested in this treatment should discuss with their healthcare provider about the possibility of participating in clinical trials or the latest approved treatment options for their specific condition.

Aspect Details
Drug Name Giredestrant (also known as GDC-9545, RO7197597, RG6171)
Drug Class Selective Estrogen Receptor Degrader (SERD)
Administration Oral, typically 30 mg once daily
Cancer Types Studied ER-positive, HER2-negative breast cancer (early-stage and metastatic)
Trial Phases Phase II and Phase III
Combination Therapies Palbociclib, Abemaciclib, Inavolisib
Primary Outcomes Ki67 reduction, Progression-Free Survival, Complete Cell Cycle Arrest
Secondary Outcomes Overall Survival, Objective Response Rate, Safety Profile
Unique Features Window-of-opportunity studies, Neoadjuvant and Adjuvant settings
Patient Populations Postmenopausal women, Premenopausal women (with LHRH agonist)

FAQ

  • What is giredestrant? Giredestrant is a highly potent, non-steroidal, oral selective estrogen receptor antagonist and degrader (SERD). It is being studied as a potential treatment for estrogen receptor-positive (ER+) breast cancer.
  • What types of breast cancer is giredestrant being studied for? Giredestrant is being investigated for various types of breast cancer, including early-stage and metastatic ER-positive, HER2-negative breast cancer. Some trials are also studying its use in specific subtypes like Grade 1 endometrial cancer.
  • How is giredestrant administered? Giredestrant is typically administered orally once daily. In most trials, the dosage is 30 mg taken daily on a continuous schedule.
  • What are some of the potential benefits of giredestrant? Clinical trials are investigating giredestrant's potential to improve outcomes such as progression-free survival, overall survival, and tumor response rates. It is also being studied for its ability to reduce tumor cell proliferation and induce complete cell cycle arrest.
  • Are there any side effects associated with giredestrant? As with all medications, giredestrant may have side effects. The clinical trials are carefully monitoring for adverse events and evaluating the safety profile of the drug. Common side effects observed in cancer treatments may include fatigue, nausea, and changes in blood cell counts, but specific side effects for giredestrant are still being determined through these trials.

Ongoing Clinical Trials on Giredestrant

  • A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study on the Effectiveness of Abemaciclib, Inavolisib, and Giredestrant in Patients with Early HR-positive/HER2-negative Breast Cancer

    Recruiting

    1 1
    Investigated drugs:
    France Greece Italy Spain

  • Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Finland France Germany Greece +7

  • Study of Abemaciclib and Giredestrant for Patients with Early Stage ER-Positive, HER2-Negative Breast Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effectiveness and Safety of Cyclophosphamide Monohydrate and Drug Combination for Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Italy Spain

  • Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Denmark France Germany Greece +5

  • Study of Giredestrant for Patients with Grade 1 Endometrial Cancer

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Italy Poland

  • Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Germany Greece Italy Spain

  • Study of Giredestrant, Triptorelin, and Anastrozole in Premenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    France Germany Hungary Ireland Italy Spain +1

  • Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Hungary Italy Poland +2

Glossary

  • Estrogen Receptor-Positive (ER+): A type of breast cancer that has cells with receptors that bind to the hormone estrogen, potentially stimulating cancer growth.
  • HER2-Negative: Refers to breast cancer cells that do not have a high amount of a protein called HER2 on their surface.
  • Neoadjuvant Treatment: Treatment given before the main treatment, usually before surgery, to shrink a tumor or slow the cancer's growth.
  • Adjuvant Treatment: Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Ki67: A protein in cells that increases as they prepare to divide into new cells. A measure of Ki67 in tumor cells helps to predict how fast the cancer may grow.
  • Complete Cell Cycle Arrest (CCCA): When cancer cells stop dividing and growing completely.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and excreted by the body.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Circulating Tumor DNA (ctDNA): Fragments of DNA from cancer cells found in the bloodstream, used to monitor cancer progression or treatment response.

References

  1. https://clinicaltrials.gov/study/NCT05634499
  2. https://clinicaltrials.eu/trial/study-on-giredestrant-or-tamoxifen-for-premenopausal-women-with-early-er-positive-her2-negative-breast-cancer/
  3. https://clinicaltrials.gov/study/NCT03916744
  4. https://clinicaltrials.gov/study/NCT04436744
  5. https://clinicaltrials.gov/study/NCT04546009
  6. https://clinicaltrials.gov/study/NCT04961996
  7. https://clinicaltrials.gov/study/NCT05306340